Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of “Moderate Buy” by Brokerages

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has earned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $39.3333.

Several equities analysts have recently commented on ETON shares. HC Wainwright raised their price target on Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen raised shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday, March 20th. Finally, B. Riley Financial upped their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, March 20th.

Institutional Trading of Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ETON. Millennium Management LLC increased its holdings in shares of Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after acquiring an additional 217,042 shares during the period. Goldman Sachs Group Inc. raised its holdings in Eton Pharmaceuticals by 34.9% in the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after purchasing an additional 45,341 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after buying an additional 31,596 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Eton Pharmaceuticals by 98.8% during the second quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock valued at $8,450,000 after buying an additional 294,617 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at about $172,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Up 2.8%

Shares of NASDAQ ETON opened at $25.36 on Thursday. Eton Pharmaceuticals has a 52-week low of $11.09 and a 52-week high of $25.99. The firm has a market capitalization of $691.92 million, a price-to-earnings ratio of -140.88 and a beta of 1.19. The stock has a 50 day moving average price of $18.06 and a 200 day moving average price of $17.72. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.57.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.60%. The firm had revenue of $21.28 million for the quarter, compared to the consensus estimate of $20.58 million. Sell-side analysts expect that Eton Pharmaceuticals will post -0.14 earnings per share for the current year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.